Congenital Amegakaryocytic Thrombocytopenia

Discussion

Congenital Amegakaryocytic Thrombocytopenia (CAMT) is a rare, congenital disorder evident in infancy, characterized predominantly by isolated thrombocytopenia and megakaryocytopenia without associated physical anomalies. The disorder stems from mutations in the c-MPL gene, which encodes the thrombopoietin (TPO) receptor, essential for megakaryocytopoiesis—the process that governs the development of megakaryocytes, the bone marrow cells responsible for platelet production. Children with CAMT often face a nearly inevitable progression to bone marrow failure, which impacts all three hematopoietic cell lines over time.

This condition is further classified into two types based on the nature of the mutation:

1. Type 1 CAMT (CAMT-1): This type results from mutations like stop codons or frameshifts that remove the intracellular domain of the MPL receptor, disrupting its function entirely. Such children present with severe thrombocytopenia at birth, are at an increased risk of intracranial haemorrhage, and typically advance to bone marrow failure by around 33 months of age.
2. Type 2 CAMT (CAMT-2): This form is caused by splicing defects or amino acid substitutions that affect the receptor’s glycosylation, diminishing its ability to interact with thrombopoietin. While the receptor’s function is reduced, not entirely lost, children with CAMT-2 experience milder, often transient, thrombocytopenia during their first year. Bone marrow failure occurs more slowly, generally between ages three and six.

Genetic Variability and CAMT

Not all cases of CAMT can be attributed directly to mutations in the MPL gene. Other genetic anomalies, such as those in the HOXA11 and MECOM genes, which regulate megakaryocyte differentiation, or the RBM8A gene, which leads to thrombocytopenia-absent radius syndrome, also contribute to the disease. Additional proposed causes include an X-linked form of CAMT and specific anti-HLA A2 antibodies.

Pathophysiology of CAMT

The development of megakaryocytes starts from hematopoietic stem cells (HSCs) in the bone marrow, progressing through several stages of differentiation reliant on thrombopoietin (THPO). THPO is vital for increasing the number, size, and ploidy of megakaryocytes. Its receptor, MPL, is crucial for these cells to progress from progenitors to mature megakaryocytes and eventually produce platelets.

Clinical Presentation and Diagnosis

CAMT typically manifests with significant thrombocytopenia early in life, potentially as early as the first day or month. Initial symptoms can include purpura, intracranial bleeds, and other haemorrhagic complications. The diagnosis is generally confirmed via bone marrow biopsy showing reduced or absent megakaryocytes and genetic testing for mutations in the MPL gene.

A family history of thrombocytopenia may be present. No characteristic congenital phenotypic abnormalities are associated with CAMT. Some studies have noted neurological defects like strabismus, cerebellar agenesis, hypoplasia of the corpus callosum and brainstem, facial malformations, and cortical dysplasia. The mechanism behind the neurological findings is unclear. One possibility is that the absence or deficiency of MPL in the brain, as seen in CAMT, can lead to developmental delay. The other hypothesis considers the long-term intracranial neurological sequelae.

Treatment Considerations for Congenital Amegakaryocytic Thrombocytopenia (CAMT)

1. Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): HSCT remains the sole curative treatment for CAMT, particularly for patients with mutations in the c-Mpl gene, which is most common. Optimal outcomes require early transplantation, ideally before the onset of pancytopenia, to minimize risks such as multiple transfusions, alloimmunization, and infections. HLA typing is recommended at diagnosis to facilitate donor selection. The average age for HSCT in CAMT patients is 38 months, with a range from 7 to 89 months. Conditioning regimens typically include busulfan, cyclophosphamide, and total body irradiation, aiming for a fully myeloablative effect with survival rates around 80%. However, these regimens are associated with significant risks, including pulmonary, mucosal, and hepatic toxicity, and potential long-term infertility. Discussions about fertility preservation are essential. Recent advancements have included the use of less toxic, non-myeloablative protocols that preserve fertility and reduce overall toxicity, improving patient outcomes.
2. Supportive Treatment: Supportive care is critical for managing CAMT and includes irradiated, leukocyte-reduced platelet transfusions and the use of antifibrinolytics, such as tranexamic acid. The use of nonsteroidal anti-inflammatory drugs and aspirin should be avoided to reduce bleeding risks. In cases of pancytopenia, treatment may require packed red blood cells and antibiotics to manage or prevent infections.
3. Thrombopoietin Receptor Agonists: For patients with thrombopoietin (THPO) mutations, treatment options include romiplostim, a THPO peptide mimetic, and eltrombopag, a small molecule MPL receptor agonist that can induce necessary conformational changes in the receptor. These treatments, however, do not benefit patients with c-Mpl gene mutations, as their issue lies with the receptor itself rather than THPO production.
4. Experimental Therapies: The exploration of new treatments for CAMT includes gene therapy using lentiviral vectors to repair the c-Mpl gene, although this method raises concerns about potential leukemogenicity effects. CRISPR-Cas9 gene editing techniques have also been employed to directly correct the genetic defects. Additionally, experimental pharmacological agents such as LGD-4665, minibodies, and diabodies are under investigation. These agents aim to stimulate defective MPL receptors to enhance megakaryocyte proliferation and function. These therapies remain experimental and are used primarily within clinical trial settings or under special access programs.

Overall, the management of CAMT requires a comprehensive approach that includes both definitive therapies like HSCT and supportive measures to manage symptoms and complications, alongside ongoing research into innovative treatment modalities.